AstraZeneca's (AZN) Lynparza Granted Priority Review by the FDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to AstraZeneca's (AZN) Lynparza Granted Priority Review by the FDA

2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch

November 29, 2021 6:45 AM EST

Shares of Merck (NYSE: MRK) are down 1.7% in pre-open Monday after Citi analyst Andrew Baum downgraded to Neutral from Buy with a price target of $85.00 per share from the prior $105.00.

First, the analyst sees a high probability that Merck will terminate islatravir development in the coming months amid strong regulatory... More

JPMorgan Reiterates Overweight Rating on AsztraZeneca PLC (AZN:LN) (AZN)

November 29, 2021 5:33 AM EST

JPMorgan analyst James Gordon reiterated an Overweight rating and GBP100.00 price target on AsztraZeneca PLC (AZN:LN) (NASDAQ: AZN).

... More

AstraZeneca hopeful its antibody cocktail will work on new COVID variant

November 26, 2021 12:54 PM EST

LONDON (Reuters) - AstraZeneca said on Friday it was hopeful its antibody cocktail against COVID-19 would retain efficacy against a new variant that is spreading in South Africa, and was also examining whether the variant was resistant to its vaccine.

"As with any new emerging variants, we are... More